Neurogene Stock (NASDAQ:NGNE)
Previous Close
$19.82
52W Range
$12.49 - $74.49
50D Avg
$46.80
200D Avg
$39.05
Market Cap
$223.88M
Avg Vol (3M)
$216.21K
Beta
-
Div Yield
-
NGNE Company Profile
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.